AbCellera Biologics Inc (NASDAQ:ABCL) shares traded 7.45% higher at $3.75 on Wall Street last session.
ABCL stock price is now 43.87% away from the 50-day moving average and 38.04% away from the 200-day moving average. The market capitalization of the company currently stands at $1.12B.
On February 22, 2024, The Benchmark Company Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock keeping its target price maintained at $9, while ‘KeyBanc Capital Markets’ rates the stock as ‘Overweight’
A total of 24.97% of the company’s stock is owned by insiders.
During the past 12 months, AbCellera Biologics Inc has had a low of $1.89 and a high of $4.09. As of last week, the company has a debt-to-equity ratio of 0.07, a current ratio of 10.15, and a quick ratio of 10.15. The fifty day moving average price for ABCL is $2.6066 and a two-hundred day moving average price translates $2.716625 for the stock.
The latest earnings results from AbCellera Biologics Inc (NASDAQ: ABCL) was released for 2025-03-31. The net profit margin was -726.23% and return on equity was -15.59% for ABCL. The company reported revenue of $4.24 million for the quarter, compared to $9.95 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -57.45 percent.
